Hyaluronan based porous nano-particles enriched with growth factors for the treatment of ulcers: a placebo-controlled study

Abstract

The present study describes the production of hyaluronan based porous microparticles by a semi-continuous gas anti-solvent (GAS) precipitation process to be used as a growth factor delivery system for in vivo treatment of ulcers. Operative process conditions, such as pressure, nozzle diameter and HYAFF11 Ò solution concentrations, were adjusted to optimize particle production in terms of morphology and size. Scanning electron microscopy (SEM) and light scattering demonstrated that porous nano-structured particles with a size of 300 and 900 nm had a high specific surface suitable for absorption of growth factors from the aqueous environment within the polymeric matrix. Water acted as a plasticizer, enhancing growth factor absorption. Water contents within the HY-AFF11 Ò matrix were analyzed by differential scanning calorimetry (DSC). The absorption process was developed using fluorescence dyes and growth factors. Immunohistochemical analysis confirmed the high efficiency of absorption of growth factor and a mathematical model was generated to quantify and qualify the in vitro kinetics of growth factor release within the polymeric matrix. In vivo experiments were performed with the aim to optimize timed and focal release of PDGF to promote optimal tissue repair and regeneration of full-thickness wounds.

Effects of serum on cytotoxicity of nano- and micro-sized ZnO particles

“…Moos et al noted that nano-sized ZnO was more toxic than micrometer-sized ZnO toward human colon cancer cells (RKO) (Moos et al 2010). Nair et al revealed that the toxicity of ZnO NPs was greater than that of ZnO microparticles toward human osteoblast cancer cells (MG-63) (Nair et al 2009). Furthermore, Hanley et al also reported significantly greater cytotoxicity of 4-nm ZnO NPs relative to 20-nm ZnO NPs (Hanley et al 2009).…”

Biomaterials and Nanotherapeutics for Enhancing Skin Wound Healing

“…Currently, PDGF-BB is the only growth factor that is FDA approved for diabetic foot ulcers, which makes PDGF-based therapies even more translational. Hyaluronan-based porous NPs enriched with PDGF-BB have been shown to be highly effective for the treatment of ulcers in a placebo-controlled study in rats (Zavan et al, 2009). Fibroblast growth factor-2 (FGF-2) has been successfully microencapsulated in gelatin preserving biological activity and thus allows for their use in tissue engineering, therapeutic angiogenesis, gene therapy, and drug delivery applications (Young et al, 2005).…”

Drug Carrier Interaction With blood: a Critical Aspect for High-Efficient Vascular-Targeted Drug Delivery Systems

“…While there is still insufficient data to allow full characterization of VTC toxicity in blood, existing evidence suggests this is more of an issue for nanoparticles than it is for microparticles [138]. Similarly, the VTC material type and surface characteristic all affect potential toxicity.…”